Our
Products

OUR INNOVATIVE PLATFORM TECHNOLOGY PROVIDES THE CAPABILITY TO PROACTIVELY FULFILL AND SUSTAIN A STOCKPILE OF AN ANTHRAX VACCINE IN A COST-EFFECTIVE AND EFFICIENT MANNER UNPARALLELED BY OUR COMPETITORS.

Through leveraging our platform technology, Pfenex is currently partnered with the U.S. government on the development of a next generation rPA based anthrax vaccine.

Pfenex is developing Px563L, a novel rPA based anthrax vaccine candidate, in response to the United States government’s unmet demand for increased quantity, stability and dose sparing regimens of anthrax vaccine. The development of Px563L is currently funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority, or BARDA, via a $143.5 million advanced development contract. Specifically, our product is differentiated in terms of stability, clinical safety and efficacy, cost and manufacturing infrastructure to support long-term production.